Abstract
COVID-19, the disease associated in December 2019 with the novel coronavirus SARS-CoV-2, was observed for the first time in China and then spread worldwide becoming pandemic. Currently, there is still no licensed specific antiviral treatment for the human coronavirus disease and a vaccine will not be ready soon. However, based on experience from the use of other antiviral agents to treat similar virusses, some treatment options have been tried with some efficacy. Clinical trials for future therapies are still ongoing. In the meantime, prevention, control, active communication and investment in research are the only ways to overcome this challenge.
Original language | English |
---|---|
Pages (from-to) | 833-836 |
Number of pages | 4 |
Journal | International Journal of Clinical Pharmacy |
Volume | 42 |
Issue number | 3 |
DOIs | |
Publication status | Published - Jun 2020 |
Keywords
- Antiviral Agents/pharmacology
- Betacoronavirus/drug effects
- COVID-19
- China
- Coronavirus Infections/drug therapy
- Humans
- Pandemics
- Pneumonia, Viral/drug therapy
- SARS-CoV-2